U.S. FOOD AND DRUG ADMINISTRATION WARNS COMPANIES ABOUT CBD CLAIMS
The FDA recently sent a warning letter to CBD manufacturers about “unfounded” claims being made about their products, according to U.S. News.
CBD took off years ago when it was introduced as a health supplement in the U.S. These companies source their CBD products from industrial hemp, which contains less than 1% THC. As long as the THC level is no higher than 0.3%, it is not considered a controlled substance.
With this kind of accessibility, CBD’s popularity skyrocketed in all 50 states. This of course led to a mountain of anecdotal evidence, ultimately painting the compound as a cure-all.
Naturally, this did not sit well with the Food and Drug Administration – nor should it sit well with consumers.
There is no denying that CBD has benefits. The question is whether many of the reported benefits are true.
Research is being done into several claims about CBD, specifically anxiety, depression and pain relief. While studies so far are promising, they are not conclusive.
The only actual confirmed benefit of CBD is its effect on Lennox Gastaut Syndrome and Dravet Syndrome – two severe types of epilepsy that do not typically respond to conventional treatment. This led to Epidiolex, the first FDA-approved pharmaceutical drug derived from CBD for the sole purpose of treating LGS and Dravet.
It may be useful for other conditions as well, but until we know which areas truly do respond to CBD treatment, the FDA and doctors will not get behind other uses.
The FDA was firm in its warning, especially since some of the reported benefits are not only untested, but could also deter people from seeking legitimate treatment.
Many companies claim CBD will do things like treat severe addiction or fix diseases that are incurable or difficult to stop.
In a press release, FDA commissioner Scott Gottleib warned manufacturers and the public:
“I believe these are egregious, over-the-line claims and we won’t tolerate this kind of deceptive marketing to vulnerable patients…the FDA stands ready to protect consumers from companies illegally selling CBD products that claim to prevent, diagnose, treat, or cure serious diseases, such as cancer, Alzheimer’s disease, psychiatric disorders and diabetes.”
Many of these claims are not entirely unfounded. Cannabis is known to have neuroprotective properties, while some terpenes are believed to help reduce the growth of cancer cells.
But again, these are based on little data that is mostly anecdotal. It could very well be true, but until it is conclusively proven, we need to be careful about what we say and – more importantly – what we believe.
WeedAdvisor’s Role in Education
Although WeedAdvisor very much supports CBD and other cannabis products, we also understand that medical cannabis is not a cure-all. We do not deny that there is probably a lot of unknown potential with CBD, but it is our firm belief that claims should not be reiterated without solid evidence to back them.
As much as we want to report that CBD can treat and cure a wide range of illnesses, we refuse to publish anything that cannot be verified through conclusive research. Our job is to educate the public, not push false hope.
That being said, we will continue to monitor advancements in CBD research and happily report new findings as they develop.